The results of pharma are good but worry of tariff, you will have to walk better in the market – Deepan Mehta – Pharma Results are good but there are concerns about tarifs it will be better to be selective in the market dipan mehta

Market Outlook: The Indian market is roaming in a realm these days. The market is waiting for a big trigger. What should investors do in such a market? Talking about the market ahead and outlook Elixir Equites director Deepan Mehta Said that there is a lot of disappointment from the earning season, especially from the results of bank and NBFC. It was expected here that the improvement in liquidity, lower interest rate, good demand were seen to see higher pre -provisioning profits. But nothing like this happened. Bank and NBFC have more weightage in Sensex-Nifty, due to which the market sideways appeared. At the same time, the results of pharma were good but Trump is a very big cloud of tariff. So I believe that this is not a very good earning season.

He further stated that although there was good growth in specialty chemicals, infrastructure construction companies, power distribution equipment companies. He further said that the results of IT should not be special. Talking on the metal sector, Dipan Mehta said that we are away from the metal sector due to cyclicity. There is a need to be selective in the metal sector because the markets can also be selective later.

Will have to walk better in the market

The results of L&T, M&M, Eicher Motors were quite good. There is a good scope visible there. There are also 8-10 companies of the Nifty 50 index where there is a possibility of good growth later. In such a situation, I believe that I have to walk selective in the market.

CDMO Space is quite like

Talking on pharma shares, Deepan Mehta said that pharma is a safe sector and secular. Its results have been better, but the concern of tariff remains on it. The results of diagnostic companies have also been much better. CDMO space is very much liked in this sector, focus must be done there. For investment in pharma sector, companies with hospitals, diagnostic and CDMO space can be invested in good valuation companies, there is a possibility of further good returns.

(Disclaimer: The ideas given on Moneycontrol.com have their own personal views. The website or management is not responsible for this. Money control advice to users to seek the advice of the Setted Experts before making any investment decisions.

Source link

Leave a Comment